Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Under the terms of the deal, Bedford, Mass.-based Stoke (STOK) will retain exclusive rights for the treatment called zorevunersen in the U.S., Canada and Mexico, while Cambridge, Mass.-based Biogen ...
Biogen price target lowered to $135 from $138 at Piper Sandler
Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the ...
Biogen (NASDAQ:BIIB) Price Target Lowered to $241.00 at HC Wainwright
Biogen (NASDAQ:BIIB – Free Report) had its price target trimmed by HC Wainwright from $300.00 to $241.00 in a report issued ...
Biogen (NASDAQ:BIIB) Price Target Cut to $210.00 by Analysts at Truist Financial
Biogen (NASDAQ:BIIB – Free Report) had its target price lowered by Truist Financial from $220.00 to $210.00 in a research ...
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Cowen cuts Biogen stock price target to $200, maintains Buy rating
TD Cowen analysts adjusted their outlook on Biogen (NASDAQ:BIIB) shares, reducing the price target to $200 from the previous $275, while sustaining a Buy rating on the stock. The revision reflects ...
Biogen price target lowered to $225 from $231 at RBC Capital
RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 ...
Biogen Analysts Lower Their Forecasts After Q4 Results
The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales ...
Barchart on MSN6d
Stocks Settle Mixed as Chip Stock Strength Lifts the Nasdaq
Wednesday closed down -0.27%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.50%, and the Nasdaq 100 Index ...